Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 345-353

  Yamada, Atsushi ^a,b   Fujii, Satoshi ^a   Daiko, Hiroyuki ^a   Nishimura, Mitsuyo ^a   Chiba, Tsutomu ^b   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

BMI1; EZH2; P53; Squamous cell carcinoma of the esophagus

Indexed keywords

BMI1 PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SIZE; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; EPITHELIUM; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78651241548     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.868     Document Type: Article

References (44)

1. Sparmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856, 2006.
2. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA and Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
3. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
4. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TLJ and Visakorpi T: EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122: 595-602, 2008.
5. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP and Akslen LA: Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168-1174, 2006.
6. Mimori K, Ogawa K, Okamoto T, Sudo T, Inoue H and Mori M: Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31: 376-380, 2005. (Pubitemid 40521303)
7. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K and Yokozaki H: Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484-491, 2006.
8. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K and Ito H: High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 45: 39-46, 2009.
9. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-5335, 2003.
10. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-5769, 2004.
11. Croonquist PA and van Ness B: The polycomb group protein enhancer of zeste analog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24: 6269-6280, 2005.
12. Bryant RJ, Cross NA, Eaton CL, Hamdy FC and Cunliffe VT: EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67: 547-556, 2007.
13. Visser HPJ, Gunster MJ, Kluin-Nelemans HC, Manders EMM, Raaphorst FM, Meijer CJLM, Willemze R and Otte AP: The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112: 950-958, 2001.
14. Chen H, Tu SW and Hsieh JT: Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280: 22437-22444, 2005.
15. Fujii S and Ochiai A: Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric carcinoma cells. Cancer Sci 99: 738-746, 2008.
16. Fujii S, Ito K, Ito Y and Ochiai A: Enhencer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332, 2008.
17. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack JR and Wirth T: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202-4212, 2008.
18. Wong CF and Tellam RL: MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 283: 9836-9843, 2008.
19. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA and Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.
20. Pietersen AM, Horlings HM, Hauptmann M, Langer¢d A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ and van Lohuizen M: EZH2 and BMI1 inversely correlated with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10: R109, 2008.
21. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK and Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203: 217-224, 2004.
22. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V and Zeng YX: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232, 2006.
23. Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, Dimri GP, Christensen R, Han T and Park NH: Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 96: 126-133, 2007.
24. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T and Nakanuma Y: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882, 2008.
25. Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A and Yokosuka O: Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 40: 1304-1311, 2009.
26. Qin ZK, Yang JA, Ye YL, Zhang X, Xu LH, Zhou FJ, Han H, Liu ZW, Song LB and Zeng MS: Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 9: 61, 2009.
27. Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, Hubscher SG, van Lohuizen M, Adams DH and Young LS: The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 95: 1202-1211, 2006.
28. Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K and Matsuoka K: Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. Int J Oncol 29: 1555-1560, 2006.
29. Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K and Matsuoka K: Identification of target antigens in specific immunotherapy for renal cell carcinoma. J Urol 177: 1157-1162, 2007.
30. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063, 2007.
31. Hamilton SR, Aaltonen LA (eds): World Health Organization classification of tumors: pathology and genetics of tumors of the digestive system. IARC Press, Lyon, pp11-19, 2000.
32. Yasuda M, Kuwano H, Watanabe M, Toh Y, Ohno S and Sugimachi K: p53 expression in squamous dysplasia associated with carcinoma of the oesophagus: evidence for field carcinogenesis. Br J Cancer 83: 1033-1038, 2000.
33. Egashira A, Morita M, Kakeji Y, Sadanaga N, Oki E, Honbo T, Ohta M and Maehara Y: p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries. Cancer Sci 98: 1152-1156, 2007.
34. Kaneko K, Katagiri A, Konishi K, Kurahashi T, Ito H, Kumekawa Y, Yamamoto T, Muramoto T, Kubota Y, Nozawa H, Makino R, Kushima M and Imawari M: Study of P53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus. Br J Cancer 96: 492-498, 2007.
35. Sobin LH and Wittekind C (eds): TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, New York, NY, pp60-64, 2002.
36. Oota M, Takeda A, Leu TL, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Kobayashi S, Gunji Y, Suzuki T, Ochiai T and Shimada H: Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 9: 23-28, 2002.
37. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P and Eng C: Breast-cancer stromal cells with TP53 mutations and nodal metastasis. N Engl J Med 357: 2543-2551, 2007.
38. Guimaraes DP, Oliveira IM, De Moraes E, Paiva GR, Souza DM, Barnas C, Olmedo DB, Pinto CE, Faria PA, De Moura Gallo CV, Small IA, Ferreira CG and Hainaut P: Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 124: 272-279, 2009.
39. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R and Hainaut P: Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 71: 79-87, 1997.
40. He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF and Xie D: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 127: 138-147, 2010.
41. Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS and Xia JC: Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 535-541, 2008.
42. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, Knizetova P, Hajduch M, Klein J, Kolek V, Radova L and Kolar Z: Prognostic value of BMI-1 oncoprotein expression in NSNLC patients: a tissue microarray study. J Cancer Res Clin Oncol 134: 1037-1042, 2008.
43. Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK, Lee SJ, Kong G, Lee JE, Kim JS, Kim JH, Yang JH and Nam SJ: Expression of Bmi-1 protein in tumor tissue is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat 113: 83-93, 2009.
44. Bachmann IM, Puntervoll HE, Otte AP and Akslen LA: Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 21: 583-590, 2008.